stockrow
Friday 6 November 2026
Export RXST’s income statement to Excel — free account
RxSight, Inc.
RXST Healthcare Medical Devices
RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024.
- Revenue
- −19.0%
- EPS
- −62.1%
- Free cash flow
- +2,591.1%
Quarter to September 2026, against a year earlier
4.50
0.04
−0.88%
Follow RXST
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 2 | 15 | 23 | 49 | 89 | 140 | 134 | 122 | +97.9% | 147 | 149 | 167 | +7.6% | |
| Gross margin, % | — | — | — | (81.17) | 11.62 | 19.99 | 43.52 | 60.36 | 70.71 | 76.60 | 76.13 | +157.8 pt | ||||||
| EBT | — | — | — | 126 | 28 | (49) | (67) | (49) | (27) | (39) | (53) | n/m | ||||||
| EBT margin, % | — | — | — | 5,633.38 | 188.25 | (215.46) | (136.20) | (54.55) | (19.59) | (28.91) | (43.69) | (5,662.3) pt | ||||||
| Net income | — | 0 | — | 108 | 28 | (49) | (67) | (49) | (27) | (39) | (53) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.08 | 3.96 | 1.66 | 1.77 | 2.59 | 3.60 | 3.29 | 2.92 | +85.4% | |||||
| Earnings | — | — | — | 0.95 | 0.91 | (3.57) | (2.41) | (1.41) | (0.71) | (0.95) | (1.28) | n/m | ||||||
| Cash flow | — | — | — | (1.47) | (9.50) | (3.28) | (2.13) | (1.21) | (0.44) | (0.38) | 0.57 | (20.2%) | ||||||
| Capex | — | — | — | 0.00 | (0.68) | (0.14) | (0.09) | (0.14) | (0.14) | (0.09) | (0.12) | n/m | ||||||
| Free cash flow | — | — | — | (1.47) | (10.18) | (3.42) | (2.21) | (1.35) | (0.58) | (0.47) | 0.45 | (17.2%) | ||||||
| Book value | — | — | — | 0.83 | 0.72 | 10.15 | 3.25 | 4.65 | 7.24 | 6.75 | 6.11 | +41.8% | ||||||
| Shares, m | — | — | — | 28 | 4 | 14 | 28 | 34 | 39 | 41 | 41 | +6.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | 4.31 | 4.31 | 6.78 | 7.21 | 14.18 | 9.55 | 3.17 | 1.52 | 7.1 | ||||||
| P/B | — | — | — | 0.00 | 0.00 | 1.11 | 3.93 | 7.87 | 4.75 | 1.54 | 0.72 | 2.7 | ||||||
| EV/Sales | — | — | — | 2.85 | 2.85 | 1.49 | 5.87 | 12.97 | 7.99 | 1.61 | (0.41) | 5.1 | ||||||
| EV/FCF | — | — | — | (1.09) | (1.09) | (0.72) | (4.70) | (24.89) | (49.97) | (11.23) | (2.70) | (13.4) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (41) | (35) | (45) | (59) | (42) | (17) | (16) | 24 | (14.8%) | |||||
| Capex | — | — | — | (4) | (3) | (2) | (2) | (5) | (5) | (4) | (5) | (1.1%) | ||||||
| Free cash flow | — | — | — | (41) | (38) | (47) | (61) | (46) | (22) | (19) | 19 | (11.6%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 82 | 70 | 165 | 117 | 148 | 268 | 261 | 240 | +21.4% | |||||
| Net debt | — | — | — | (75) | (45) | (120) | (66) | (127) | (237) | (228) | (255) | +20.3% | ||||||
| Shareholders’ equity | — | — | — | 23 | 3 | 138 | 90 | 160 | 281 | 276 | 255 | +51.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 47.32 | 3.19 | (33.19) | (38.94) | (29.22) | (10.96) | (12.36) | (16.44) | (59.7) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (176.71) | (163.06) | (94.34) | (52.34) | (63.34) | (16,845.67) | (63.3) pt | ||||||
| ROE | — | — | — | 0.00 | (1.03) | 45.85 | (58.52) | (38.85) | (12.43) | (13.99) | (20.10) | (14.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 171 | 221 | 292 | 374 | 498 | 461 | — | +21.9% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.09 | 0.10 | 0.17 | 0.24 | 0.28 | 0.29 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
RxSight, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INFU InfuSystems Holdings, Inc. | $270.1M | 32.0× | 33.0× | +2.59% (above 0%: growing) | +33.33% (above 0%: growing) | −66.54% (below 0%: shrinking) | 57.98% | 11.24% | Compare |
| QSI Quantum-Si Incorporated | $256.1M | — (loss-making) | — (loss-making) | −61.59% (below 0%: shrinking) | n/m | +37.48% (above 0%: growing) | 34.91% | (11,215.09%) | Compare |
| PROF Profound Medical | $251.3M | — (loss-making) | — (loss-making) | +85.86% (above 0%: growing) | n/m | +47.93% (above 0%: growing) | 78.13% | (79.56%) | Compare |
| LAB Standard BioTools Inc. | $245.7M | 1.8× | — (loss-making) | −0.85% (below 0%: shrinking) | n/m | +73.32% (above 0%: growing) | 55.86% | (101.98%) | Compare |
| ELMD Electromed, Inc. | $221.8M | 19.4× | 18.6× | +11.64% (above 0%: growing) | +57.69% (above 0%: growing) | −25.15% (below 0%: shrinking) | 78.71% | 19.70% | Compare |
| TLSI TriSalus Life Sciences, Inc. | $217.4M | — (loss-making) | — (loss-making) | +1.73% (above 0%: growing) | n/m | −41.29% (below 0%: shrinking) | 86.78% | (86.03%) | Compare |
| RXST RxSight, Inc. | $190.4M | — (loss-making) | — (loss-making) | −18.97% (below 0%: shrinking) | n/m | +2,591.06% (above 0%: growing) | 73.62% | (75.32%) | |
| STIM Neuronetics, Inc. | $185.2M | — (loss-making) | — (loss-making) | +12.51% (above 0%: growing) | n/m | +237.71% (above 0%: growing) | 52.17% | 1.29% | Compare |
| INGN Inogen, Inc | $179.7M | — (loss-making) | — (loss-making) | +3.04% (above 0%: growing) | n/m | −51.15% (below 0%: shrinking) | 45.51% | (5.36%) | Compare |
| Median of peers | $233.8M | 19.4× | — | +2.82% | — | +6.17% | 56.92% | (42.46%) |
Pay and ownership Proxy statement filed 28 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 4.65m | (2.16m) | 92.62 |
| 2024 | 6.98m | 5.12m | 305.60 |
| 2023 | 3.08m | 11.80m | 358.40 |
| 2022 | 1.03m | 1.25m | 112.62 |
Ownership
Directors and executive officers, together
10.05%
BlackRock, Inc.
5.78%
Millennium Management, LLC
5.30%
Artisan Partners Asset Management Inc.
5.21%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement